Mistelikirjallisuus

       Lisätietoja tutkimuksista 

Forschungsinstitut Havelhöhe, Berlin (DE)

Institut für angewandte Erkenntnistheorie und medizinische Methodologie e. V. Freiburg i.Br. (DE)

Verein für Krebsforschung e.V., Forschungsinstitut HISCIA (CH)

Medizinische Sektion der Freien Hochschule für Geisteswissenschaft

www.mistel-therapie.de

Tutkimukset aakkosjärjestyksessä A-K

(Tutkimukset aakkosjärjestyksessä L-Z)

Antony S, Kuttan R and Kuttan G. Role of natural killer cells in iscador mediated inhibition of metastasis by adoptive immunotherapy. Immunol Invest, 2000;29:219-231.

 

Antony S, Kuttan R and Kuttan G. Effect of viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells. J Exp Clin Cancer Res, 1997;16:159-162

Antony S, R Kuttan and G Kuttan: Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Immunol Invest. 1999; 28: 1-8.

 

Auerbach L, Dostal V, Vaclavik-Fleck I, Kubista E, Rosenberger A, Rieger S, Tröger W and Schierholz J M. Signifikant höherer Anteil aktivierter NKZellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiv-randomisierten doppelblinden Studie [Significant Higher Level of Activated NK-Cells in Patients with Breast Cancer Receiving Viscurn alburn Extract] during Chemotherapy. In: Scheer R, Bauer H. Becker R et al. Fortschritte  in der Misteltherapie. Stand der Forschung und klinischen Anwendung. Essen, KVC Verlag, 2005. S.543-554.

 

Augustin M, Bock P R, Hanisch J, Karasmann M and Schneider B. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Arzneimittelforschung, 2005;55:38-49. DOI: 10.1055/s-0031-1296823.

 

Axtner J, Steele M, Kroz M, Spahn G, Matthes H and Schad F. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer, 2016;16:579. DOI: 10.1186/s12885-016-2594-5.

Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E and Haim N. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer, 2013;49:1058-1064 DOI: 10.1016/j.ejca.2012.11.007.

 

Bar-Sela, G. White-Berry Mistletoe (Viscum album L.) as complementary treatment in cancer: Does it help? European Journal of Integrative Medicine 2011;3:e55-e62. DOI: 10.1016/j.eujim.2011.03.002.

 

Bauer C, Oppel T, Rueff F and Przybilla B. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. Ann Allergy Asthma Immunol, 2005;94:86-89. DOI:10.1016/S1081-1206(10)61291-4.

 

Baumgartner S, Flückiger H, Kunz M, Scherr C, Urech K. Evaluation of preclinical assays to investigate an anthroposophic pharmaceutical process applied to mistletoe (Viscum album L.) extracts. Evidence-Based Complementary and Alternative Medicine 2014:1–8. DOI: https:// doi.org/10.1155/2014/620974. https://www.hindawi.com/journals/ecam/2014/620974/

 

Becker H und JM Scher (2005). Kurzer Überblick über die Inhaltsstoffe der Mistel (Viscum album L.).  In: Scheer R,  Bauer R.  Becker H,  Fintelmann V Kemper FH Kemper und Schilcher H (Hrsg.): Fortschritte in der Misteltherapie, Aktueller Stand der Forschung und klinische Anwendung. S. 3-11.  KVC Verlag Essen 2005. ISBN 3-933351-49-9.

 

Ben-Arye E, Dahan O, Shalom-Sharabi I, Samuels N. Inverse relationship between reduced fatigue and severity of anemia in oncology patients treated with integrative medicine: understanding the paradox. Supportive Care in Cancer 2018; 10 pp. DOI: 10.1007/s00520-018-4271-5

 

Beuth J, Schneider B and Schierholz J M. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res, 2008;28:523-527.

 

Beztsinna N,de Matos MBC, Walther J, et al. Quantitative analysis of receptor-mediated uptake and pro-apoptotic activity of mistletoe lectin-1 by high content imaging. Nature Scientific Reports 2018;8:2768. DOI: https://doi.org/10.1038/s41598- 018-20915-y.

 

Biegel U, Stratmann N, Knauf Y, Ruess K, Reif M, Wehrend A. Postoperative adjuvante Therapie mit einem Mistelextrakt (Viscum album ssp. album) bei Hündinnen mit Mammatumoren. Complementary Medicine Research 2017;24(3):349-357. DOI: 10.1159/000485228.

 

Bock PR, Hanisch J, Matthes H and Zänker KS. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients. Inflamm Allergy Drug Targets, 2014;13:105-111.

 

Bock PR, Friedel WE, Hanisch J, Karasmann M and Schneider B. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung, 2004;54:456-466. DOI: 10.1055/s-0031-1296999.

 

Bodungen von U, Ruess K, Reif M, Biegel U.Kombinierte Anwendung von Strahlentherapie und adjuvanter Therapie mit einem Mistelextrakt (Viscum album L.) zur Behandlung des oralen malignen Melanoms beim Hund: Eine retrospektive Studie. Complementary Medicine Research 2017;24:358-363.

 

Bonucci M, Pastore C, Ferrera V, Fiorentini C, Fabbri A. Integrated cancer treatment in the course of metastatic pancreatic cancer: Complete resolution in 2 cases. Integrative Cancer Therapies 2018:17(3):994-999. DOI: 10.1177/1534735418755479.

 

Bouzek T. Misteltherapie bei Patienten mit Hirntumoren: 3 Kasuistiken. Der Merkurstab. Zeitschrift für Anthroposophische Medizin 2012;65(3):249-256. DOI: https://doi.org/10.14271/DMS-19966-DE.

 

Braedel-Ruoff S. Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials. Forsch Komplementmed, 2010;17:63-73. DOI: 10.1159/000288702.

 

Brandenburger M, Simoes-Wüst A P, Rostock M, Rist L and Saller R. Quality-of-life of cancer patients during mistletoe therapy - An exploratory study with the additional use of questionnaires (Lebensqualität von Krebspatienten während der Misteltherapie - Eine explorative Studie mit dem zusätzlichen Einsatz von Fragebögen). In: Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, et al., editors. Die Mistel in der Tumortherapie 3, Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2013.

 

Burger A M, Mengs U, Kelter G, Schuler J B and Fiebig H H. No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res 2003;23:3801-3806.

 

Burkhart J, Walchli C, Heusser P, Weissenstein U, Baumgartner S and  Andres AC. In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide. Altern Ther Health Med. 2010; 16: 40-48.

 

Büssing A, Raak C and Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med, 2012;2012:219402. DOI: 10.1155/2012/219402.

 

Büssing A, Girke M, Heckmann C, Schad F, Ostermann T and Kröz M. Validation of the self-regulation questionnaire as a measure of health in quality of life research. Eur J Med Res 2009;14:223-227.

 

Büssing A, M Bischof, W Hatzmann, F Bartsch, D Soto-Vera, EM Fronk, M Gmeindl and GM Stein: Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res. 2005; 25: 4753-4757.

 

Büssing A, Vervecken W, Wagner M, Wagner B, Pfuller U and Schietzel M. Expression of mitochondrial Apo2.7 molecules and caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. Cytometry, 1999;37:133-139.

 

Büssing A, Rosenberger A, Stumpf C  and Schietzel M. Development of lymphocyte subsets in tumor patients after subcutaneous administration of mistletoe extracts. Forsch Komplementarmed 1999;6(4):196–204.

 

Büssing A and M Schietzel: Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999; 19: 23-28.

 

Büssing A, Schaller G and Pfuller U. Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Res, 1998;18:4291-4296.

 

Büssing, A. Induction of apoptosis by the mistletoe lectins: A review on the mechanisms of cytotoxicity mediated by Viscum album L. Apoptosis (1996) 1: 25.

 

Büssing A, Suzart K, Bergmann J, Pfuller U, Schietzel M and Schweizer K. Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett, 1996;99:59-72. DOI: 10.1016/0304-3835(95)04038-2.

Büssing A, Regnery A and Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett, 1995;94:199-205. DOI: 10.1016/0304-3835(95)03850-v.

Büssing A, Regnery A and Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett, 1995;94:199-205. DOI: 10.1016/0304-3835(95)03850-v.

 

Büssing A, Azhari T, Ostendorp H, Lehnert A and Schweizer K. Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer, 1994;30A:1836-1841. DOI: 10.1016/0959-8049(94)00299-k.

 

De Matos MBC, Miranda BS, Nuari YR, et al. Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery. Journal of Drug Targeting 2019;27:681–698. DOI: https://doi.org/10.1080/ 1061186X.2019.1579819.

De Matos MBC, Beztsinna N, Heyder C, et al. Thermosensitive liposomes for triggered release of cytotoxic proteins. European Journal of Pharmaceutics and Biopharmaceutics 2018;132:211– 221. DOI: https://doi.org/10.1016/ j.ejpb.2018.09.010.

 

Doehmer J, Eisenbraun J. Assessment of extracts from mistletoe (Viscumalbum) for herb-drug interaction by inhibition and induction of cytochromeP450 activities. Phytother Res 2012;26:11-7. DOI: 10.1002/ptr.3473

doi: 10.1097/MD.0000000000013420.

 

Dold U, Edler L, Maurer H, Muller D, Sakellariou B, Trendelenburg F, et al. Krebszusatztherapie beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom. Multizentrische kontrollierte Studie zur Prufung der

Wirksamkeit von Iscador und Polyerga. Stuttgart, New York: G. Thieme Verlag; 1991.

Dorka R, Engelmann W, Hellrung W. Chronobiologische Untersuchungen an Viscum album L. und ihre pharmazeutische Relevanz. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H (Hrsg). "Fortschritte in der Misteltherapie, Aktueller Stand der Forschung und klinische Anwendung", 662 Seiten, KVC Verlag Essen 2005, ISBN 3-933351-49-9: 23–34.

 

Dorka R. Zur Chronobiologie der Mistel. In: Scheer R, Becker H, Berg PA (Hrsg). Grundlagen der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung, 525 Seiten, Stuttgart: Hippokrates Verlag Stuttgart; 1996, ISBN 3-7773-1239-8: 28–45.

 

Drozdoff L, Klein E, Kiechle M and Daniela P. Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complementary and Alternative Medicine 2018; 18(1):259. 2018. 

Eisenbraun J. Intravesikaler Mistelextract bei Patienten mit nicht-muskelinvasivem Harnblasenkarzinom: Eine Phase III-Wirksamkeitsstudie - Aktueller Stand. n: Scheer R, Alban S, Becker H, Beer A-M, Blaschek W, Kreis W, et al., editors. Die Mistel in der Tumortherapie 4 Aktueller Stand der Forschung und klinische Anwendung: KVC Verlag, Essen, 2016, S. 345-354.

 

Eisenbraun J. Mistelextrakt bei Patienten mit nichtmuskelinvasivem Harnblasenkarzinom - Ergebnisse einer einarmigen Phase Ib/IIa Dosiseskalationsstudie. In: Scheer R, Alban S, Becker H, Beer A-M, Blaschek W, Kreis W, et al., editors. Die Mistel in der Tumortherapie 4 Aktueller Stand der Forschung und klinische Anwendung: KVC Verlag, Essen, 2016, S. 331-334.

 

Eisenbraun J, Scheer R, Kroz M, Schad F and Huber R. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine, 2011;18:151-157. DOI: 10.1016/j.phymed.2010.06.013.

 

Elluru SR, JP Duong van Huyen, S Delignat, MD Kazatchkine, A Friboulet, SV Kaveri and J Bayry: Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer. 2008; 8: 161.

 

Elluru S, JPD Huyen van, B Wootla, S Delignat, F Prost, VS Negi and SV Kaveri: Tumor regressive effects of Viscum album preparations – Exploration of immunomodulatory mechanisms. Medicina. 2007; 67: 85-89.

 

Elluru S, JP Duong Van Huyen, S Delignat, F Prost, J Bayry, MD Kazatchkine and SV Kaveri: Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung. 2006; 56: 461-466.

 

Elsasser-Beile U, Voss M, Schuhle R and Wetterauer U. Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal, 2000;14:255-259. DOI: 10.1002/1098-2825(20001212)14:6<255::aid-jcla1>3.0.co;2-j.

 

Engdal S and Nilsen O G. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res, 2009;23:906-912. DOI: 10.1002/ptr.2750.

 

Eom JS, Ahn HY, Mok JH, Lee G, Jo E-J, Kim M-H, Lee K, Kim KU, Park H-K, Lee MK. Pleurodesis using mistletoe extract delivered via a spray catheter during semirigid pleuroscopy for managing symptomatic malignant pleural effusion. Respiration 2018;95:177-181. DOI: 10.1159/000481869.

 

Ernst E, K Schmidt and MK Steuer-Vogt: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer. 2003; 107: 262-267.

 

Escher P, Eiblmeier M, Hetzger I, Rennenberg H. Seasonal and spatial variation of carbohydrates in mistletoes (Viscum album) and the xylem sap of its hosts (Populus x euamericana and Abies alba). Physiologia Plantarum 2004;120(2):212–219. DOI: https://doi.org/10.1111/j.0031- 9317.2004.0230.x.

 

Felenda JE, Turek C, Stintzing FC. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells. Journal of Ethnopharmacology 2019;236:100-107. DOI: 10.1016/j.jep.2019.02.047.

Felenda JE, Gruber K, Pacifico S, Turek C, Beckmann C, Stintzing FC. In-vitro-Untersuchungen zur Weidenmistel an verschiedenen humanen Tumorzelllinien. Zeitschrift für Phytotherapie 2019;40(3):112-119. DOI: 10.1055/a-0799-7042.

 

Felenda JE, Gruber K and Stintzing F. In-vitro-Untersuchungen zur Hemmung der Angiogenese und der Tumorzellmigration durch einen wässrigen Extrakt aus Viscum album ssp. album, Mali. June 2019. Deutsche Zeitschrift für Onkologie 2019;51(02):81-88. DOI: 10.1055/a-0827-9646.

Fellmer KE. A clinical trial of Iscador. Br Homeopath J. 1968; 57(01): 43–7.

  

Franz H, Ziska P and Kindt A: Isolation and properties of three lectins from mistletoe (Viscum album L.). Biochem J. 1981; 195: 481-484.

 

Franz M (2003). Struktur und biologische Aktivitäten der chitinbindenden Mistellektine. Dissertation, University Tübingen.

 

Freuding M, Keinki C, Kutschan S, Micke O, Buentzel J and Huebner J. Mistletoe in oncological treatment: a systematic review: part 2: quality of life and toxicity of cancer treatment. J Cancer Res Clin Oncol 2019; 145(4):927–939.

Freuding M, KeinkiC, Micke O, Buentzel J and Huebner J. Mistletoe in oncological treatment: a systemic review: part 1: survival and safety. J Cancer Res Clin Oncol 2019;145: 695–707. 

 

Friedel W E, Matthes H, Bock P R and Zanker K S. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 2009;7:137-145.

 

Friess H, Beger H G, Kunz J, Funk N, Schilling M and Buchler M W. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 1996;16:915-920.

 

Fritz P, Dippon J, Müller S, Goletz S, Trautmann C, Pappas X, Ott G, Brauch H, Schwab M, Winter S, Mürdter T, Brinkmann F, Faisst S, Rössle S, Gerteis A, Friedel G. Is mistletoe treatment beneficial in invasive breast cancer? A new approach to an unresolved problem. Anticancer Research 2018;38:1585-1593. DOI: 10.21873/anticanres.12388.

 

Gamerith G, Amann A, Schenk B, Auer T, Lentzen H, Mügge DO, Cima KM, Löffler-Ragg J, Hilbe W, Zwierzina H. Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells. Oncology Letters 2017;14(5):5563-5568. DOI: 10.3892/ol.2017.686.

  

Grah C, Kurzeja A, Matthes B, Eichberger A, Wüstfeld A, Kunc K, Weissenstein U, Thieme C, Müssig A, Schad F and Reif M. Immun-Checkpoint-Inhibition plus Viscum album L.- Extrakt beim Lungenkarzinom. Pneumologie 2019; 73(S 01) DOI: 10.1055/s-0039-1678248. Conference: 60 Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., 2019.

 

Greenlee H, MJ DuPont-Reyes, LG Balneaves, LE Carlson, MR Cohen, G Deng, JA Johnson, M Mumber, D Seely, SM Zick, LM Boyce and D Tripathy: Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017; 67: 194-232.

 

Greenlee H, LG Balneaves, LE Carlson, M Cohen, G Deng, D Hershman, M Mumber, J Perlmutter, D Seely, A Sen, SM Zick, D Tripathy and O Society for Integrative: Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014; 2014: 346-358.

 

Grossarth-Maticek R and Ziegler R. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). European Journal of Medical Research, 2008;13:107-120.

 

Grossarth-Maticek R and Ziegler R. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed, 2007;14:140-147. DOI: 10.1159/000102956.

Grossarth-Maticek R and Ziegler R. Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 2007;57(10):665–678. 

Grossarth-Maticek R and Ziegler R. Efficacy and safety of the long-term treatment of melanoma with a mistletoe preparation (Iscador). Schweizerische Zeitschrift für GanzheitsMedizin, 2007, 19(6):325-332.

Grossarth-Maticek R and Ziegler R. Prospective Controlled Cohort Studies on Long-Term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador®). Forschende Komplementärmedizin, 2006;13:285-292. DOI: 10.1159/000095378.

Grossarth-Maticek R, Ziegler R. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a reanalysis.

Eur J Med Res. 2006 Nov; 11(11): 485–95.

Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R. Synergieeffekte von Selbstregulation und Misteltherapie (Iscador) auf die Uberlebenszeit bei Krebspatienten. Schweiz Zschr Ganzheitsmedizin. 2004; 16(2): 81–9.

Grossarth-Maticek R, Kiene H, Baumgartner S M and Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001;7:57-66, 68-72, 74-56 passim.

 

Gutsch J, Werthmann P G, Rosenwald A and Kienle G S. Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under Viscum album Extracts After Resistance to R-CHOP: A Case Report. Anticancer Res, 2018;38:5363-5369. DOI: 10.21873/anticanres.12865.

Gutsch J, S Rieger and D Schlodder (2013). Observational study on treatment of lymphocytic non-Hodkin lymphoma (CLL) with in-process-standardized Viscum album products Helixor P or A - Clinical course and safety. In: In: Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, et al., editors.Die Mistel in der Tumortherapie 3, Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2013.

 

Gutsch J, S Rieger, JM Schierholz and D Schlodder (2008). Observational study on treatment with standardized Viscum album extracts (VA-E) in lymphocytic non-Hodgkin's lymphoma (CLL) - safety and course. In:  Scheer R, Alban S, Becker H et al.  Die Mistel in der Tumortherapie 2. Essen, KVC Verlag, 2009.

 

Gutsch J. Außergewöhnlicher Krankheitsverlauf bei metastasierendem Mammakarzinom unter Misteltherapie nach pseudoallergischer Reaktion. In: Scheer R, Bauer R, H B, Berg PA, Fintelmann V, editors. Die Mistel in der Tumortherapie Grundlagenforschung und Klinik. Essen: KVC Verlag; 2001. S. 379-387.

Günzler M, Salzer G. Iscadortherapie in derNachbehandlung operierter Carcinome. Österr Ärzteztg. 1969; 24(20): 2290–4.

Günzler M, Osika C, Salzer G. Ergebnisse von Resektion und Nachbehandlung beim Magenkarzinom. Wien Klin Wochenschr. 1968 Feb; 80(6): 105–6.

Hajtó T, Fodor K, Perjesi P and Nemeth P. Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine. Evid Based Complement Alternat Med, 2011;2011:298972. DOI: 10.1093/ecam/nep191.

 

Hajtó T, Hostanska K, Frei K, Rordorf C and Gabius HJ. Increased secretion of tumor necrosis factor α, interleukin 1, and interleukin 6 by human mononuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Research 1990;50(11):3322-3326. 

 

Hajtó T. Immunomodulatory effects of iscador: a Viscum album preparation. Oncology 1986; 43(1):51–65. DOI:10.1159/000226420.

 

Hoffmann J, Hajtó T. Iscadorbehandlung beim metastasierenden Mammakarzinom. Krebsgeschehen. 1982;(3): 71–5.

Hall A H, Spoerke D G and Rumack B H. Assessing mistletoe toxicity. Ann Emerg Med 1986;15:1320-1323.

Hamre HJ, Witt CM, Kienle GS, Glockmann A, Stefan NW and Helmut K. Predictors of outcome after 6 and 12 months following anthroposophic therapy for adult outpatients with chronic disease: a secondary analysis from a prospective observational study. BMC Research Notes 2010;3:218. 

Heinzerling L, von Baehr V, Liebenthal C, von Baehr R and Volk H D. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol, 2006;26:347-359. DOI: 10.1007/s10875-006-9023-5.

 

Hirschberger S, Giesder M. Beschreibung und Hintergründe der Iscucin- Herstellung bei der WALA Heilmittel GmbH. Der Merkurstab. Zeitschrift für Anthroposophische Medizin 2021;74(3):227-232. DOI: https://doi.org/10.14271/DMS-21358-DE

 

Hoffmann J. Die Iscador-Behandlung bei Lebermetastasen. Krebsgeschehen. 1979;(6):172–5.

Horneber MA, Bueschel G, Huber R, Linde K and Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev, 2008:CD003297. DOI: 10.1002/14651858.CD003297.pub2.

 

Huber R and Gründemann C. Die Wirkungen der Mistelsubstanz auf das Immunsystem und mögliche therapeutische Implikationen. Der Merkurstab, Zeitschrift für Antroposophische Medizin, 2018;71:265-268.

 

Huber R, Schlodder D, Effertz C, Rieger S and Tröger W. Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer. BMC Complementary and Alternative Medicine (2017) 17:465. DOI 10.1186/s12906-017-1971-1

 

Huber R, Lüdtke H, Wieber J and Beckmann C. Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects. BMC Complementary and Alternative Medicine, vol. 11, no. 116, 2011. DOI: doi.org/10.1186/1472-6882-11-116.

 

Huber R, Classen K, Werner M and Klein R. In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (Viscum album L.) extracts Iscador applied to healthy individuals. Arzneimittelforschung, 2006;56:447-456. DOI: 10.1055/s-0031-1296811.

 

Huber R, Rostock M, Goedl R, Ludtke R, Urech K, Buck S and Klein R. Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects. Eur J Med Res, 2005;10:411-418.

 

Huebner J, Freuding M, Keinki C, Micke O, and Buentzel J. Answer to the letter to the editors by Matthes and colleagues regarding our systematic reviews on mistletoe. J Cancer Res Clin Oncol 2019;145(9):2409-2410.

Hutt N, Kopferschmitt-Kubler M, Cabalion J, Purohit A, Alt M and Pauli G. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergologia et immunopathologia, 2001;29:201-203.

 

Janssen O, Scheffler A and Kabelitz D. In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung, 1993;43:1221-1227.

 

Kelter G and HH Fiebig: Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. Arzneimittelforschung. 2006; 56: 435-440.

 

Kempenich R, Willeke M, Meyer U. Das Prostatakarzinom und seine Behandlung mit Iscucin® Populi - Einführung und klinische Fälle aus der Praxis. Der Merkurstab. Zeitschrift für Anthroposophische Medizin 2009;62(3):255-261. DOI: https://doi.org/10.14271/DMS-19439-DE .

 

Kienle G S, Mussler M, Fuchs D and Kiene H. The Subjective Dimension of Integrative Cancer Care: A Qualitative Study Exploring the Perspectives, Themes, and Observations of Experienced Doctors from the Area of Anthroposophic Medicine. Explore (NY), 2018;14:342-351. DOI: 10.1016/j.explore.2018.03.007.

 

Kienle G S, Mussler M, Fuchs D and Kiene H. Intravenous Mistletoe Treatment in Integrative Cancer Care: A Qualitative Study Exploring the Procedures, Concepts, and Observations of Expert Doctors. Evid Based Complement Alternat Med, 2016;2016:4628287. DOI: 10.1155/2016/4628287.

 

Kienle GS, Grugel R and Kiene H. Safety of higher dosages of Viscum album L. in animals and humans - systematic review of immune changes and safety parameters. BMC Complementary and Alternative Medicine 2011, 11:72. 

 

Kienle GS and Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther, 2010;9:142-157. DOI: 10.1177/1534735410369673.

Kienle, G.S., A. Glockmann, M. Schink, and H. Kiene Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 2009;28:79. DOI: 1756-9966-28-79 [pii]10.1186/1756-9966-28-79.

 

Kienle GS, Kiene H. Cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007; 12:103-119.

 

Kienle GS, Kiene H, Albonico HU: Anthroposophic Medicine: Effectiveness, Utility, Costs, Safety. Stuttgart, New York: Schattauer Verlag; 2006.

Kienle GS, Kiene H. Kontrollierte klinische Studien zur Misteltherapie der Krebserkrankung – eine systematische Übersicht. In: Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper F, Schilcher H. (Hrsg.) KVC Verlag, Essen 2005;405-421.

Kienle GS, F Berrino, A Büssing, E Portalupi, S Rosenzweig and H Kiene: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res. 2003; 8: 109-119.

 

Kienle GS and H Kiene H. Verträglichkeit, Nebenwirkungen, Überempfindlichkeitsreaktionen, Toxizität. Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Stuttgart, New York, Schattauer Verlag, 2003. S.591-60.

 

Kim S, Kim K-C, Lee C. Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells. Phytomedicine 2017;36:183-193. DOI: 10.1016/j.phymed.2017.09.017.

 

Kim K-C, Yook J-H, Eisenbraun J, Kim B-S and Huber R. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma–a randomized, controlled pilot study. BMC Complementary and Alternative Medicine, 2012;12:172.

 

Kleeberg U R, Suciu S, Brocker E B, Ruiter D J, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont A M and Society E M G i c w t G C. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. Eur J Cancer, 2004;40:390-402.

 

Kleijnen J, Knipschild P. Mistletoe treatment for cancer - review of controlled trials in humans. Phytomedicine, 1994;1:255-260.

Klein R, Franz M, Wacker R, Classen K, Scheer R, von Laue HB, Stoeva S and Voelter W. Demonstration of antibodies to the chitin-binding mistletoe lectin (cbML) in tumor patients before and during therapy with an aqueous mistletoe extract. Eur J Med Res 2004;9:316-322.

Klein R, Classen K, Berg PA, Lüdtke R, Werner M  and Huber R. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. European Journal of Medical Research, 2002;7(4):155–163, 2002.

 

Klett CY and Anderer FA. Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from viscum album extract. Arzneimittelforschung 1989;39:1580-1585.

 

Kovacs E, Link S and Toffol-Schmidt U. Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador. Arzneimittelforschung, 2006;56:467-473. DOI: 10.1055/s-0031-1296814.

 

Kovacs E, Hajto T and Hostanska K. Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Eur J Cancer, 1991;27:1672-1676.

 

Kröz M, Mehl A, Didwiszus A, Gelin-Kröz B, Reif M, Berger B, ten Brink F, Zerm R, Girke M, Gutenbrunner C and Büssing A. Reliability and first validity of the inner correspondence questionnaire for painting therapy (ICPTh) in a sample of breast cancer patients. Complementary Therapies in Medicine. 2019;42:355-360.

 

Kröz M, Büssing A, Reif M, Pranga D, Schad F, Zerm R, Matthes H and Girke M. (2016).Besteht eine Indikation für die Misteltherapie in der Behandlung von Cancer-related Fatigue und Insomnie bei Krebspatienten? –  Ein Review. In: Scheer R, Alban S, Becker H, Beer A-M, Blaschek W, Kreis W, et al., editors. Die Mistel in der Tumortherapie 4. Aktueller Stand der Forschung und klinische Anwendung: KVC Verlag, Essen, 2016, S.287-298.

 

Kröz M, Büssing A, von Laue B H, Reif M, Feder G, Schad F, Girke M and Matthes H. Reliability and validity of a new scale on internal coherence (ICS) of cancer patients. Health Qual Life Outcomes, 2009;7:59. DOI:10.1186/1477-7525-7-59.

 

Kröz M, Zerm R, Reif M, von Laue B H, Schad F, Bussing A, Bartsch C, Feder G and Girke M. Validation of the German version of the Cancer Fatigue Scale (CFS-D). Eur J Cancer Care (Engl), 2008;17:33-41. DOI: 10.1111/j.1365-2354.2007.00799.x

 

Kuehn JJ (2009). Viscum album L. Pini in der Behandlung des Non-Hodgkin-Lymphoms - Wirksamkeit und Risikoeinschätzung einer subkutanen Misteltherapie im Rahmen einer retrospektiven Fallkontrollstudie. In:  Scheer R, Alban S, Becker H et al.  Die Mistel in der Tumortherapie 2. Essen, KVC Verlag, 2009: S.353-373.

 

Kuehn JJ. Treatment responses to Viscum album pini (Iscador P) in non-Hodgkin's lymphoma exploring a new therapeutic route. Medicina 2007;67:107-114.

 

Kunz C, Heiligtag HR, Hintze A and K Urech K (2013). Topische Behandlung des Basalzellkarzinoms mit Viscum album, lipophiler Extrakt 10%, Unguentum - Eine Fallserie-Studie, S.315-322. In: Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, et al., editors. Die Mistel in der Tumortherapie 3, Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2013.

 

Kuttan G and Kuttan R: Reduction of leukopenia in mice by "viscum album" administration during radiation and chemotherapy. Tumori 1993;79:74-76.

 

Kuttan G, Vasudevan DM and R Kuttan R. Isolation and identification of a tumour reducing component from mistletoe extract (Iscador). Cancer Lett 1988;41:307-314.

 

Kuttan R and Kuttan G. Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Immunol Invest, 1999;28:1-8.

Tutkimukset aakkosjärjestyksessä L-Z